Abstract
Aim and objectives: The aim of this study was to determine cost of illness and cost of utility in the study population and making recommendations to decrease the economic burden of the treatment by following the life style modifications. Methodology: It is a cross sectional pharmacoepidemiological study. Totally 132 diabetic patients both in-patients and out patients of medical and surgical departments in a secondary level referral hospital were included in this study which was conducted for a period of 6 months. All patients with diabetes type-II, continuing anti diabetic drugs (Metformin, Glibenclamide and Insulin,) for their diabetes management are included and patients who are diagnosed as Diabetic type-I and pregnancy and pediatric patients were excluded. Data was analyzed by Carlson comorbidities Index.
 Results: A total of 132 diabetic patients were included, in which male and famales were nearly equal in number. Based upon the comorbid conditions, it was found that the most of the subjects (69%) were suffering with diabetes along with hypertension and 9.9% are having comorbidity of hypertension & acute renal failure along with DM and treatment costs more economic burden to the patients. The average utility of drugs is more for the combination of Metformin+Glibenclamide+Insulin than metformin+glibenclamide.
 Conclusion: Finally we concluded that study place is a rural area and most of people are with poor knowledge and having lack of awareness on both disease and treatment. By applying Charlson Co morbidities index we found the patient’s economic status by which we found that many of the diabetic patients facing economic burden, especially daily wager are feeling much difficulty to face even therapy cost also. In co morbidities side, we noticed 55% of the study population are having diabetes with hypertension. Although all the patients were provided with education regarding their disease and drugs for improving their quality of life, but it has an influence on very few people.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Current Innovations in Advanced Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
